Related Experiment Video
Updated: Jun 22, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Icariside II in NSCLC and COVID-19: Network pharmacology and molecular docking study
Qing Kong1,2,3, Huahe Zhu1,2, Jingcheng Dong1,2
1Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Background:
Patients with non-small cell lung cancer (NSCLC) are susceptible to coronavirus disease-2019 (COVID-19), but current treatments are limited. Icariside II (IS), a flavonoid compound derived from the plant epimedin, showed anti-cancer,anti-inflammation and immunoregulation effects. The present study aimed to evaluate the possible effect and underlying mechanisms of IS on NSCLC patients with COVID-19 (NSCLC/COVID-19).
Methods:
NSCLC/COVID-19 targets were defined as the common targets of NSCLC (collected from The Cancer Genome Atlas database) and COVID-19 targets (collected from disease database of Genecards, OMIM, and NCBI). The correlations of NSCLC/COVID-19 targets and survival rates in patients with NSCLC were analyzed using the survival R package. Prognostic analyses were performed using univariate and multivariate Cox proportional hazards regression models. Furthermore, the targets in IS treatment of NSCLC/COVID-19 were defined as the overlapping targets of IS (predicted from drug database of TMSCP, HERBs, SwissTarget Prediction) and NSCLC/COVID-19 targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis of these treatment targets were performed aiming to understand the biological process, cellular component, molecular function and signaling pathway. The hub targets were analyzed by a protein-protein interaction network and the binding capacity with IS was characterized by molecular docking.
Results:
The hub targets for IS in the treatment of NSCLC/COVID-19 includes F2, SELE, MMP1, MMP2, AGTR1 and AGTR2, and the molecular docking results showed that the above target proteins had a good binding degree to IS. Network pharmacology showed that IS might affect the leucocytes migration, inflammation response and active oxygen species metabolic process, as well as regulate the interleukin-17, tumor necrosus factor and hypoxia-inducible factor-1 signaling pathway in NSCLC/COVID-19.
Conclusions:
IS may enhance the therapeutic efficacy of current clinical anti-inflammatory and anti-cancer therapy to benefit patients with NSCLC combined with COVID-19.
Insights
Icariside II (IS) shows potential in treating non-small cell lung cancer (NSCLC) patients with COVID-19 by targeting key inflammatory and cellular processes. This flavonoid compound may improve existing anti-cancer and anti-inflammatory therapies.
Area of Science:
- Oncology
- Virology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) patients are vulnerable to COVID-19 with limited treatment options.
- Icariside II (IS), a flavonoid from Epimedium, exhibits anti-cancer, anti-inflammatory, and immunoregulatory properties.
- This study investigates the potential of IS in treating NSCLC patients co-infected with COVID-19.
Purpose of the Study:
- To evaluate the therapeutic effects of Icariside II (IS) on non-small cell lung cancer (NSCLC) patients with COVID-19.
- To elucidate the underlying molecular mechanisms of IS action in NSCLC/COVID-19.
- To identify potential therapeutic targets for combined NSCLC and COVID-19 treatment.
Main Methods:
- Integrated analysis of NSCLC and COVID-19 common targets.
- Survival analysis and Cox regression for prognostic evaluation.
- Network pharmacology, including Gene Ontology and KEGG enrichment analysis.
- Protein-protein interaction network construction and molecular docking for target validation.
Main Results:
- Identified key targets for IS treatment in NSCLC/COVID-19: F2, SELE, MMP1, MMP2, AGTR1, and AGTR2, with favorable molecular docking results.
- Network pharmacology indicated IS influences leukocyte migration, inflammation, and reactive oxygen species metabolism.
- IS may modulate key signaling pathways including IL-17, TNF, and HIF-1.
Conclusions:
- Icariside II (IS) demonstrates potential as an adjunct therapy for NSCLC patients with COVID-19.
- IS may enhance the efficacy of current anti-cancer and anti-inflammatory treatments.
- Further research into IS could lead to improved therapeutic strategies for this patient population.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...